Myocardial Tissue Reverse Remodeling After Guideline-Directed Medical Therapy in Idiopathic Dilated Cardiomyopathy

Circ Heart Fail. 2021 Jan;14(1):e007944. doi: 10.1161/CIRCHEARTFAILURE.120.007944. Epub 2020 Nov 13.

Abstract

Background: The prognosis of patients with idiopathic dilated cardiomyopathy (DCM) has improved remarkably in recent decades with guideline-directed medical therapy. Left ventricular (LV) reverse remodeling (LVRR) is one of the major therapeutic goals. Whether myocardial fibrosis or inflammation would reverse associated with LVRR remains unknown.

Methods: A total of 157 prospectively enrolled patients with DCM underwent baseline and follow-up cardiovascular magnetic resonance examinations with a median interval of 13.7 months (interquartile range, 12.2-18.5 months). LVRR was defined as an absolute increase in LV ejection fraction of >10% to the final value of ≥35% and a relative decrease in LV end-diastolic volume of >10%. Statistical analyses were performed using paired t test and student t test, logistic regression analysis, and linear regression analysis.

Results: Forty-eight (31%) patients reached LVRR. At baseline, younger age, worse New York Heart Association class, new-onset heart failure, lower LV ejection fraction, absence of late gadolinium enhancement, lower myocardial T2, and extracellular volume were significant predictors of LVRR. During the follow-up, patients with and without LVRR both showed a significant decrease of myocardial native T1 (LVRR: [baseline] 1303.0±43.6 ms; [follow-up] 1244.7±51.8 ms; without LVRR: [baseline] 1308.5±80.5 ms; [follow-up] 1287.6±74.9 ms, both P<0.001), matrix and cellular volumes while no significant difference was observed in T2 or extracellular volume values after treatment.

Conclusions: In patients with idiopathic DCM, the absence of late gadolinium enhancement, lower T2, and extracellular volume values at baseline are significant predictors of LVRR. The myocardial T1, matrix, and cell volume decrease significantly in patients with LVRR after guideline-directed medical therapy. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: ChiCTR1800017058.

Keywords: cardiomyopathy, dilated; heart failure; inflammation; magnetic resonance; myocardium.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Adult
  • Age Factors
  • Angiotensin Receptor Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Anticoagulants / therapeutic use
  • Cardiomyopathy, Dilated / diagnostic imaging
  • Cardiomyopathy, Dilated / drug therapy*
  • Cardiomyopathy, Dilated / pathology
  • Cardiotonic Agents / therapeutic use
  • Cardiovascular Agents / therapeutic use*
  • Digoxin / therapeutic use
  • Diuretics / therapeutic use
  • Extracellular Space / diagnostic imaging
  • Female
  • Humans
  • Magnetic Resonance Imaging
  • Magnetic Resonance Imaging, Cine
  • Male
  • Middle Aged
  • Mineralocorticoid Receptor Antagonists / therapeutic use
  • Practice Guidelines as Topic
  • Prognosis
  • Severity of Illness Index
  • Stroke Volume*
  • Ventricular Remodeling*
  • Warfarin / therapeutic use

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Anticoagulants
  • Cardiotonic Agents
  • Cardiovascular Agents
  • Diuretics
  • Mineralocorticoid Receptor Antagonists
  • Warfarin
  • Digoxin

Associated data

  • ChiCTR/ChiCTR1800017058